1 / 5

AbsDoc_4786_1

A 072 0226 04786 Financing AIDS and pricing antiretrovirals (ARV): the Brazilian and Mexican case RAUL MOLINA molinara_2005@yahoo.com.mx ELOY GONZÁLEZ UNIVERSIDAD AUTONOMA METROPOLITANA.

anais
Download Presentation

AbsDoc_4786_1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A 072 0226 04786Financing AIDS and pricing antiretrovirals (ARV): the Brazilian and Mexican caseRAUL MOLINA molinara_2005@yahoo.com.mx ELOY GONZÁLEZ UNIVERSIDAD AUTONOMA METROPOLITANA Background: The study focuses on the forms of HIV/AIDS financing and the pricing ARV drugs in the Brazilian and Mexican case. The financing forms are not neutral in relation to an equitable access. The public forms of financing, social security or general taxation, are more equitable than those relying on the household out-of-pocket money. People who live with HIV/AIDS in Brazil have universal access to a comprehensive treatment that includes the ARV drugs, but this it is not the case of Mexico. In Mexico health services are segmented, as well as those for people affected by HIV/AIDS, in the social security system is provided a comprehensive treatment but it is not the case for people without social security regardless of an availability improvement on ARV drugs actually. Methods: The AIDS health accounts are used to study the financing forms. For ARV drug prices the public and private information is used. Results: The main source of financing, in both countries, is public. The Brazilians AIDS mortality rate (AMR) fell down as the AIDS program was implemented and ARV drugs were included on an universal basis. The Mexican AMR is stabilized, nonetheless the AMR is 54% lower for people with social security (Instituto Mexicano del Seguro Social), a widening gap between Mexican society. The ARV drug prices in Mexico are higher than those in Brazil; Lamivudine, Saquinavir and Lopinavir-Ritonavir are highly priced in Mexico relative to Brazilian prices by 2006; As an average the ARV drug cost therapy by patient is 240% higher in Mexico than the Brazilian one by 2006. Conclusions: The Mexican health system fails to provide a comprehensive and universal health care to the treatment of HIV/AIDS thus AMR do not fall. The ARV drug therapy cost is a high burden for Mexican society which could put in jeopardy the Mexican AIDS program.

More Related